APA (7th ed.) Citation

St, E. W., Clair, Wang, L., Alevizos, I., Rees, W., Baer, A., . . . Baldini, C. (2023). OP0143 EFFICACY AND SAFETY OF DAZODALIBEP (VIB4920/HZN4920) IN SUBJECTS WITH SJÖGREN’S SYNDROME: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF OF CONCEPT STUDY. Annals of the rheumatic diseases, 82(Suppl 1), 95. https://doi.org/10.1136/annrheumdis-2023-eular.234

Chicago Style (17th ed.) Citation

St, E. W., Clair, L. Wang, I. Alevizos, W. Rees, A. Baer, W. F. Ng, G. Noaiseh, and C. Baldini. "OP0143 EFFICACY AND SAFETY OF DAZODALIBEP (VIB4920/HZN4920) IN SUBJECTS WITH SJÖGREN’S SYNDROME: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF OF CONCEPT STUDY." Annals of the Rheumatic Diseases 82, no. Suppl 1 (2023): 95. https://doi.org/10.1136/annrheumdis-2023-eular.234.

MLA (9th ed.) Citation

St, E. W., et al. "OP0143 EFFICACY AND SAFETY OF DAZODALIBEP (VIB4920/HZN4920) IN SUBJECTS WITH SJÖGREN’S SYNDROME: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF OF CONCEPT STUDY." Annals of the Rheumatic Diseases, vol. 82, no. Suppl 1, 2023, p. 95, https://doi.org/10.1136/annrheumdis-2023-eular.234.